As the addition of VEN to HMA is associated with prolonged cytopenias [21, 22] and more frequent infections [21], the addition of VEN in TP53 mutated AML is questionable and novel strategies should be pursued in this challenging to-treat population. This evidence concerns the gene TP53 and acute myeloid leukemia.